The Lymphocyte MAP-Cyrex Lab Kit:
Note: This is a test kit that will be mailed to you. It requires a blood draw. It is your responsibility to arrange the blood draw for your kit and payment of your specimen collection.
Fasting Required: No
Lab: Cyrex Laboratories
Specimen: Whole Blood
Results: Average processing time 14 business days
Note: Result turnaround times are an estimate and are not guaranteed. Our reference lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.
Special Instructions: Are there any medications, foods, conditions, or other factors that could interfere with the results of a Cyrex test? Yes. While Cyrex is unable to provide an exhaustive answer to this question due to the interactive complexities and varieties of medications and patient circumstances, the following has been noted:
- Immunosuppressant and corticosteroid drugs can reduce antibody production and cause false negative results.
- Limited assessments on the effects of aspirin, acetaminophen, and antipsychotics on Arrays 1-4 have been performed. No noticeable effects were observed.
- Inhalers can affect the results of Cyrex's oral fluid testing (Array 14). Wait two weeks after completion of inhalant dosages before collecting the specimen.
- Unknown cross-reactive epitopes from foods and microorganisms may stimulate the antibody production in the absence of a true antigen. Cyrex has already developed Array 4 in order to recognize the most common antigens in this regard.
- A gluten-free diet can cause false negative results.
- Oral fluid testing collection requires no eating one hour before and no drinking 30 minutes before collection.
- Eating a high fat meal prior to your blood draw can cause your serum specimen to be lipemic. Lipemic specimens are rejected by Cyrex Labs.
- Wait at least 60 days after the completion of steroids to do testing. It takes this period of time for the medication to clear the system and allow the normalized production of antibodies, required for immune testing, to resume.
- Patients should consult with their HCP regarding any questions or concerns they may have.
Notice: Shipments should be sent Monday through Thursday.
Description: The Lymphocyte MAP™, is an innovative test which establishes a new standard in screening the immune system. It measures the integrity of the immune system at the cellular level to help identify a patient’s immune status and immunotype(s), based on 35 key determinations. It utilizes an advanced proprietary flow cytometry method, which combines cutting-edge laser technology with monoclonal antibodies, to precisely measure the properties of living cells such as size, shape, density and granularity which results in a precise count of various lymphocyte subpopulations. This helps identify patterns of imbalance of T cells, B cells and Natural Killer cells. It then organizes these patterns into specific immunotypes to provide an invaluable picture of the immune system.
Lymphocytes and their subpopulations are the key elements of the immune system. In adults, they account for about 20-49% of the total number of white blood cells. It would be vitally important to measure decrease or increase in the percentage and number of these important lymphocytes. It is the numbers, ratios, percentages and activity level of these lymphocytes, and their subpopulations which are responsible for protection against various environmental factors, including viruses. When healthy, these NRPAs are in a precise and pre-determined relationship to one-another. It is the disruption of these finely balanced relationships which can compromise the immune function. These are NOT measured by a CBC test, which is just part of a yearly checkup. There is a significant difference between lymphocyte immunophenotyping and the complete blood count (CBC), which is used for checking the overall health of a patient. A CBC could be absolutely normal, but the patient could actually be suffering from immune dysfunction, which includes immune deficiencies, hidden inflammation, autoimmunities, hypersensitivities and allergies induced by environmental triggers. These immune disorders can be detected by the advanced immunophenotyping of lymphocytes done by Cyrex Labs.
Key Features of The Lymphocyte MAP
- Fourteen immunotypes uniquely designed to capture and highlight important immune trends revealed due to the comprehensive number of determinations tested.
- T-helper-1 or T-helper -2 Dominance (Immunotypes 6 and 7) Includes the Cyrex Fluorescence Activated Cell Test (Cyrex FACT™), a breakthrough proprietary process developed by expert Cyrex immunologists, to classify Th1/Th2 balance or imbalance, based on the specific clusters of differentiation (CD markers) on the surface membranes on Th1 or Th2 cells, and not on the measurement of Th1/Th2-associated cytokine levels in the blood, commonly used by other laboratories.
- Regulatory T cells or Tregs (Immunotype 8) maintain the balance between Th1 and Th2. A low number of Tregs may result in the breakdown in peripheral, central and oral tolerance, immune suppression, immune deficiencies, some autoimmune disorders, increased infections and cancer.
- T-helper-17 dominance. (Immunotype 9) Includes the Cyrex FACT™ process based on direct measurement of cells based on the CD markers on their surface membranes of the cells, not by measuring IL-17 levels in the blood.
- Patterns of disturbance in NK, cytotoxic NK and NK T cells. (Immunotypes 12 and 13) these immmunotypes are characterized by imbalanced natural killer (NK) cells, cytotoxic NK cells and NK T cells. They are the body’s soldiers whose job is to destroy different pathogens and varieties of cancer cells.
- Immunotype with low or high CD57+ and its combination with CD16+ NK cells and CD8+ T cells. (Immunotype 14) CD57+ NK cells are highly differentiated long-lived cells that are more efficient in the killing of pathogen-infected cells and cancers, particularly during aging. Due to their efficiency at the killing of their targets, elevations in the number of CD57+ NK cells are associated with better outcomes for patients with cancers and some autoimmune diseases, while low levels are associated with lower overall survival from cancer.
The Lymphocyte MAP can:
Lymphocyte MAP™ Determinations:
- Total Lymphocyte
- % Lymphocyte
- Total T Cell
- % T Cell
- Total B Cell
- % B Cell
- T Cell/B Cell Ratio
- Total T-Helper (CD4) Cell
- % T-Helper (CD4) Cell
- Total Cytotoxic (CD8) T Cell
- % Total Cytotoxic (CD8) T Cell
- CD4/CD8 Ratio
- Total T-Helper-1 Cell
- % Total T-Helper-1 Cell
- Total T-Helper-2 Cell
- % Total T-Helper-2 Cell
- Th1/Th2 Ratio
- Total T-Helper-17
- % Total T-Helper-17
- Total Regulatory T Cell
- % Regulatory T Cell
- Th17/Treg Ratio
- Total NK Cell
- % NK Cell
- Total Cytotoxic NK cells
- % Cytotoxic NK cells
- Total NKT (CD:56+, CD16+ T Cell)
- % NKT (CD:56+, CD16+ T Cell)
- Total CD3- CD57+ Lymphocyte
- % CD3- CD57+ Lymphocyte
- Total CD57+ CD8+ T Cell
- % CD57+ CD8+ T Cell
- Total CD57+ CD16+ NK Cell
- % CD57+ CD16+ NK Cell